MedTrace Logo

Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction

NCT06379152 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-04-23

No results posted yet for this study

Summary

Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear.

Conditions

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • Dongying Zhang, doctor · First Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-20
Primary Completion
2024-06-30
Completion
2024-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379152 on ClinicalTrials.gov